IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients′ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer
Yu, Ke-Da1,2; Zhou, Ying1,2; Liu, Guang-Yu1,2; Li, Bin1,2; He, Ping-Qing3; Zhang, Hong-Wei4; Lou, Li-Hua5; Wang, Xiao-Jia6; Wang, Shui7; Tang, Jin-Hai8; Liu, Yin-Hua9; Wang, Xiang10; Jiang, Ze-Fei11; Ma, Li-Wen12; Gu, Lin13; Cao, Ming-Zhi14; Zhang, Qing-Yuan15; Wang, Shen-Ming16; Su, Feng-Xi17; Zheng, Hong18; Li, Hong-Yuan19; Tang, Li-Li20; Sun, Sheng-Rong21; Liu, Jin-Ping22; Shao, Zhi-Ming1,2; Shen, Zhen-Zhou1,2
关键词Breast Cancer Patient Support Program Compliance Aromatase Inhibitor
刊名BREAST CANCER RESEARCH AND TREATMENT
2012-07-01
DOI10.1007/s10549-012-2059-8
134期:1页:307-313
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者National Natural Science Foundation of China ; Shanghai United Developing Technology Project of Municipal Hospitals ; Key Clinical Program of the Ministry of Health ; Zhuo-Xue Project of Fudan University ; Shanghai Committee of Science and Technology Fund 2011 Qimingxing Project ; National Natural Science Foundation of China ; Shanghai United Developing Technology Project of Municipal Hospitals ; Key Clinical Program of the Ministry of Health ; Zhuo-Xue Project of Fudan University ; Shanghai Committee of Science and Technology Fund 2011 Qimingxing Project
研究领域[WOS]Oncology
关键词[WOS]TAMOXIFEN ; THERAPY ; ADHERENCE ; WOMEN
英文摘要

Since the rate of persistence to adjuvant endocrine therapy such as 5-year aromatase inhibitors (AI) would decrease over time in patients with hormone-sensitive breast cancer, it is necessary to investigate if a patient support program could modify patients′ beliefs and improve their persistence to AI treatment. This was a prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving postmenopausal patients′ persistence to adjuvant AI medication for early stage breast cancer (NCT00769080). The primary objective was to compare the rates of 1-year persistence to upfront adjuvant AI for patients in the two observational arms (standard treatment group and standard treatment plus patient support program group). In this study, 262 patients were enrolled in the standard treatment group and 241 patients in the standard treatment plus patient support program group. The mean 1-year persistence rates were 95.9 and 95.8 % for the standard treatment group and the standard treatment plus patient support program group, respectively (P = 0.95). The mean times to treatment discontinuation were 231.2 days in the standard treatment group and 227.8 days in the standard treatment plus patient support program group, with no statistically significant difference between the two groups (P = 0.96). There was also no statistically significant difference in the reason for treatment discontinuation (P = 0.32). There was a significant relationship between the patient centered care questionnaire and poor persistence (odds ratio = 3.9; 95 % CI, 1.1-13.7; P = 0.035), suggesting that the persistence rate of patients with whom the doctor always or usually spends time is greater than that of patients with whom the doctor sometimes or never spends time. Patients′ persistence to adjuvant AI medication for postmenopausal, early stage breast cancer is relatively high in the first year and is not significantly increased by adding a patient support program to standard treatment.

语种英语
所属项目编号30971143 ; 30972936 ; 81001169 ; 81102003 ; SHDC12010116 ; 11QA1401400
资助者National Natural Science Foundation of China ; Shanghai United Developing Technology Project of Municipal Hospitals ; Key Clinical Program of the Ministry of Health ; Zhuo-Xue Project of Fudan University ; Shanghai Committee of Science and Technology Fund 2011 Qimingxing Project ; National Natural Science Foundation of China ; Shanghai United Developing Technology Project of Municipal Hospitals ; Key Clinical Program of the Ministry of Health ; Zhuo-Xue Project of Fudan University ; Shanghai Committee of Science and Technology Fund 2011 Qimingxing Project
WOS记录号WOS:000306437500031
Citation statistics
Cited Times:12[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51774
Collection北京大学第一临床医学院
作者单位1.307 Hosp Peoples Liberat Army, Beijing 100071, Peoples R China
2.Shanghai 6th Hosp, Shanghai 200233, Peoples R China
3.Peking Univ, Hosp 3, Beijing 100191, Peoples R China
4.Sichuan Univ, W China Hosp, Chengdu 610041, Peoples R China
5.Fudan Univ, Zhongshan Hosp, Shanghai 200032, Peoples R China
6.Peoples Hosp Hubei, Wuhan 430060, Peoples R China
7.Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China
8.Peoples Hosp Jiangsu, Nanjing 210029, Jiangsu, Peoples R China
9.Jiangsu Canc Hosp, Nanjing 210009, Peoples R China
10.Peking Univ, Hosp 1, Beijing 100034, Peoples R China
11.Sichuan Prov Peoples Hosp, Chengdu 610072, Peoples R China
12.Fudan Univ, Shanghai Med Coll, Dept Breast Surg, Ctr Canc, Shanghai 200032, Peoples R China
13.Fudan Univ, Shanghai Med Coll, Inst Canc, Shanghai 200032, Peoples R China
14.Zhejiang Prov Tradit Chinese Med, Hangzhou 310006, Zhejiang, Peoples R China
15.Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China
16.Tianjin Med Univ, Canc Inst & Hosp, Tianjin 300060, Peoples R China
17.Qingdao Univ, Coll Med, Affiliated Hosp, Qingdao 266003, Peoples R China
18.Harbin Med Univ, Affiliated Hosp 3, Harbin 150040, Peoples R China
19.Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510700, Guangdong, Peoples R China
20.Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou 510120, Peoples R China
21.Chongqing Med Univ, Affiliated Hosp 1, Chongqing 400016, Peoples R China
22.Central S Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China
Recommended Citation
GB/T 7714
Yu, Ke-Da,Zhou, Ying,Liu, Guang-Yu,et al. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients′ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer[J]. BREAST CANCER RESEARCH AND TREATMENT,2012,134(1):307-313.
APA Yu, Ke-Da.,Zhou, Ying.,Liu, Guang-Yu.,Li, Bin.,He, Ping-Qing.,...&Shen, Zhen-Zhou.(2012).A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients′ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.BREAST CANCER RESEARCH AND TREATMENT,134(1),307-313.
MLA Yu, Ke-Da,et al."A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients′ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer".BREAST CANCER RESEARCH AND TREATMENT 134.1(2012):307-313.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Yu, Ke-Da]'s Articles
[Zhou, Ying]'s Articles
[Liu, Guang-Yu]'s Articles
百度学术
百度学术Similar articles in
[Yu, Ke-Da]'s Articles
[Zhou, Ying]'s Articles
[Liu, Guang-Yu]'s Articles
必应学术
必应学术Similar articles in
[Yu, Ke-Da]'s Articles
[Zhou, Ying]'s Articles
[Liu, Guang-Yu]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.